Products & Pipeline
We are developing and commercializing novel Digital Therapeutics for a variety of indications including smoking cessation, major depressive disorder, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity.
CT-100: Click Neurobehavioral Intervention (CNI) Platform
Discovery
Dev/Pilot
Pivotal
CT-101
Clickotine®
Smoking Cessation
CT-152
Major Depressive Disorder (MDD)
Otsuka
CT-155
Schizophrenia
Boehringer Ingelheim
CT-132
Migraine
CT-156
Schizophrenia
Boehringer Ingelheim
CT-102
Opioid Use Disorder (OUD)
Indivior
CT-133
Multiple Sclerosis (MS)
CT-171
Atopic Dermatitis
CT-181
Obesity
CT-191
Oncology
CT-141
Clickadian™
Insomnia
CT-111
Clickheart™
Acute Coronary Syndrome
Clickotine®
CT-101An all in one, comprehensive digital smoking cessation program
Major Depressive Disorder (MDD)
CT-152Click is researching multiple cognitive exercises for the treatment of MDD.
Schizophrenia
CT-155Confidential
Migraine
CT-132Confidential
Schizophrenia
CT-156Confidential
Clickadian™
CT-141Clickadian is under development as a clinically-validated fully digital program for insomnia
Clickheart™
CT-111Clickheart is under development as a clinically-validated digital program for acute coronary syndrome
Additional Products in Research & Development
Back Pain
Bladder
Dermatitis
Disease
Pulmonary Disease